Moderna wins FDA approval for updated 2026-2027 COVID-19 vaccines targeting JN.1-lineage XFG subvariant

Reuters2026/08/27 19:58

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA cleared Moderna’s updated 2026-2027 COVID-19 vaccine formulas targeting the JN.1-lineage XFG subvariant via sBLA approvals.
Spikevax label covers high-risk patients aged 6 months to 64 years, plus all adults 65 years and older.
mNEXSPIKE label covers high-risk patients aged 12 to 64 years, plus all adults 65 years and older.
Rollout is expected in the coming days, aligning product supply with the FDA’s monovalent JN.1-lineage XFG composition guidance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608271556ACCESSWRNAPR_____1213527) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Moderna wins FDA approval for updated 2026-2027 COVID-19 vaccines targeting JN.1-lineage XFG subvariant

You may also like

Crypto prices